$45.62+64.40% · 3M
Moving avg
1W-1.72%
1M+11.27%
3M+68.65%
6M+122.54%
YTD+95.04%
1Y+189.10%
3Y+428.01%
5Y+59.79%
52-week range
$8.7359% of range$71.50
Company health
Value0/6
Growth2/6
Profitability1/6
Health2/6
Dividend0/6
Bull vs bear
Strengths
- Analysts see 26% upside to a $58 target
- Analyst consensus is "Buy"
Risks
- Currently unprofitable
- Burning free cash flow
- Highly leveraged (debt is 2.7x equity)
Key statistics
Valuation
Market cap
$3.16B
Enterprise value
$2.78B
P/E ratio (TTM)
-11.17x
P/S ratio (TTM)
167.58x
EV/EBITDA
-15.35x
Per share & returns
EPS (TTM)
-$3.81
Dividend yield
0.00%
Beta (1Y)
0.94
30-day change
+11.27%
Trading
Volume (24h)
327.47K
Previous close
$45.13
Shares outstanding
69.37M
About uniQure N.V.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Symbol
QURE
uniQure N.V. is a mid-cap healthcare company in the Biotechnology industry. Its shares are listed on NASDAQ (Netherlands) and trade under the ticker QURE.
Frequently asked questions
What is uniQure N.V.'s market cap?
uniQure N.V. (QURE) has a market capitalization of $3.16B.
What sector is uniQure N.V. in?
uniQure N.V. operates in the Healthcare sector, Biotechnology industry.
What exchange does QURE trade on?
QURE trades on NASDAQ.
Appears in
Eli Lilly and CompanyLLY
$1,220.72+0.04%
$1.15T cap
Johnson & JohnsonJNJ
$261.31+0.17%
$629.74B cap
AbbVie Inc.ABBV
$250.53+0.71%
$442.63B cap
UnitedHealth Group IncorporatedUNH
$402.71-0.71%
$365.71B cap
Roche Holding AGSWX: ROP
CHF 362.30-0.88%
$355.30B cap
Merck & Co., Inc.MRK
$134.73+1.36%
$332.76B cap
Novartis AGSWX: NOVN
CHF 123.96-0.19%
$290.28B cap
AstraZeneca PLCLON: AZN
£117.08+0.05%
$245.27B cap